Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels

By  

Current Pharmaceutical Design, Vol. 11, Iss. 21, 2005-08 ,pp. : 2699-2716

Bentham Science Publishers

Access to resources Recommend Favorite

Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients

By Malaisse Willy J  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2691-2698

Informa Healthcare

Access to resources Recommend Favorite

Imidazoline Binding Sites in the Endocrine Pancreas: Can They Fulfil Their Potential as Targets for the Development of New Insulin Secretagogues?

By  

Current Pharmaceutical Design, Vol. 7, Iss. 14, 2001-09 ,pp. : 1413-1431

Bentham Science Publishers

Access to resources Recommend Favorite

Are all insulin secretagogues equal in cardiovascular toxicity?

By  

Reactions Weekly, Vol. 1, Iss. 1348-1349, 2011-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Role of -opioid receptors in insulin release in the presence of inhibitory and excitatory secretagogues

By Garca-Barrado M.J.   Iglesias-Osma M.C.   Rodrguez R.   Martn M.   Moratinos J.  

European Journal of Pharmacology, Vol. 448, Iss. 1, 2002-07 ,pp. : 95-104

Elsevier

Access to resources Recommend Favorite